768 related articles for article (PubMed ID: 26833127)
1. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Koyama S; Akbay EA; Li YY; Aref AR; Skoulidis F; Herter-Sprie GS; Buczkowski KA; Liu Y; Awad MM; Denning WL; Diao L; Wang J; Parra-Cuentas ER; Wistuba II; Soucheray M; Thai T; Asahina H; Kitajima S; Altabef A; Cavanaugh JD; Rhee K; Gao P; Zhang H; Fecci PE; Shimamura T; Hellmann MD; Heymach JV; Hodi FS; Freeman GJ; Barbie DA; Dranoff G; Hammerman PS; Wong KK
Cancer Res; 2016 Mar; 76(5):999-1008. PubMed ID: 26833127
[TBL] [Abstract][Full Text] [Related]
2. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
3.
Pons-Tostivint E; Lugat A; Fontenau JF; Denis MG; Bennouna J
Cells; 2021 Nov; 10(11):. PubMed ID: 34831355
[TBL] [Abstract][Full Text] [Related]
4. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
[TBL] [Abstract][Full Text] [Related]
5. AXL targeting restores PD-1 blockade sensitivity of
Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
[TBL] [Abstract][Full Text] [Related]
6.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
7. Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer.
Hasegawa T; Yanagitani N; Ninomiya H; Sakamoto H; Tozuka T; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Ariyasu R; Uchibori K; Kitazono S; Horiike A; Nishio M
In Vivo; 2020; 34(5):2997-3003. PubMed ID: 32871843
[TBL] [Abstract][Full Text] [Related]
8. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
9. Emerging Therapeutic Implications of STK11 Mutation: Case Series.
Laderian B; Mundi P; Fojo T; E Bates S
Oncologist; 2020 Sep; 25(9):733-737. PubMed ID: 32396674
[TBL] [Abstract][Full Text] [Related]
10. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
[TBL] [Abstract][Full Text] [Related]
11. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
12. LKB1 modulates lung cancer differentiation and metastasis.
Ji H; Ramsey MR; Hayes DN; Fan C; McNamara K; Kozlowski P; Torrice C; Wu MC; Shimamura T; Perera SA; Liang MC; Cai D; Naumov GN; Bao L; Contreras CM; Li D; Chen L; Krishnamurthy J; Koivunen J; Chirieac LR; Padera RF; Bronson RT; Lindeman NI; Christiani DC; Lin X; Shapiro GI; Jänne PA; Johnson BE; Meyerson M; Kwiatkowski DJ; Castrillon DH; Bardeesy N; Sharpless NE; Wong KK
Nature; 2007 Aug; 448(7155):807-10. PubMed ID: 17676035
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
Gao Y; Päivinen P; Tripathi S; Domènech-Moreno E; Wong IPL; Vaahtomeri K; Nagaraj AS; Talwelkar SS; Foretz M; Verschuren EW; Viollet B; Yan Y; Mäkelä TP
Clin Cancer Res; 2022 Jan; 28(1):227-237. PubMed ID: 34667030
[TBL] [Abstract][Full Text] [Related]
14. Tumor loss-of-function mutations in STK11/LKB1 induce cachexia.
Iyengar P; Gandhi AY; Granados J; Guo T; Gupta A; Yu J; Llano EM; Zhang F; Gao A; Kandathil A; Williams D; Gao B; Girard L; Malladi VS; Shelton JM; Evers BM; Hannan R; Ahn C; Minna JD; Infante RE
JCI Insight; 2023 Apr; 8(8):. PubMed ID: 37092555
[TBL] [Abstract][Full Text] [Related]
15. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
16. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
Mazzaschi G; Leonetti A; Minari R; Gnetti L; Quaini F; Tiseo M; Facchinetti F
Curr Treat Options Oncol; 2021 Sep; 22(11):96. PubMed ID: 34524570
[TBL] [Abstract][Full Text] [Related]
17. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
[TBL] [Abstract][Full Text] [Related]
18.
Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
[No Abstract] [Full Text] [Related]
19. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
20. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
